Top Wall Street Forecasters Revamp Medtronic Expectations Ahead Of Q2 Earnings

Earnings Report - Medtronic plc is set to release its second-quarter earnings results on November 18, with analysts expecting earnings of $1.31 per share, an increase from $1.26 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.86 billion, compared to $8.4 billion in the previous year [1] Clinical Study Announcement - On October 8, Medtronic announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system in gynecological procedures [2] - Following this announcement, Medtronic's shares rose by 0.4% to close at $96.28 [2] Analyst Ratings and Price Targets - JP Morgan analyst Robbie Marcus maintained a Neutral rating and raised the price target from $90 to $100 [8] - Truist Securities analyst Richard Newitter maintained a Hold rating and increased the price target from $96 to $103 [8] - Stifel analyst Rick Wise maintained a Hold rating and raised the price target from $90 to $105 [8] - Citigroup analyst Joanne Wuensch maintained a Buy rating and increased the price target from $101 to $112 [8] - Argus Research analyst David Toung maintained a Buy rating and raised the price target from $105 to $115 [8]